The study met all of the primary and secondary endpoints, demonstrating noninferior efficacy between eflapegrastim, at a lower G‐CSF dose (3.6 mg) than pegfilgrastim (6.0 mg G‐CSF), in reducing severe neutropenia and neutropenia‐related complications, including FN, which is associated with myelosuppressive TC therapy. The gene discussed is CSF3; the disease is neutropenia.